(PharmaNewsWire.Com, November 29, 2019 ) According to a new market research report "EMEA 3D CBCT Market by Application (Dental (Oral and Maxillofacial Surgery, Implantology, Orthodontic, Endodontic) and Non-Dental (Radiology, ENT)), End User (Hospitals and Clinics, Diagnostic Centres) - Forecast to 2023", published by MarketsandMarkets™, the market is expected to reach USD 300.4 Million by 2023 from an estimated USD 194.3 Million in 2018, at a CAGR of 9.0%.
Browse 74 market data Tables and 17 Figures spread through 115 Pages and in-depth TOC on "EMEA 3D CBCT/Cone Beam CT Systems Market"
Early buyers will receive 10% customization on this report
With increasing disposable incomes, rising healthcare expenditure, and the availability of health insurance, the willingness to undergo expensive cosmetic procedures in various countries has increased. Moreover, the rising expenditure on treatments for appearance enhancements is driving the demand for dental products in the market.
By application, the dental segment accounted for the largest share of the EMEA 3D CBCT Systems Market in 2017
On the basis of application, the market is broadly segmented into dental and non-dental applications. The dental applications segment further sub segmented into implantology, oral and maxillofacial surgery, orthodontics, endodontics, and other dental applications. The non-dental applications segment is sub segmented into ENT and radiology. The dental application segment accounted for the largest share of EMEA 3D CBCT Systems Market in 2017. Large geriatric population in the European countries, technological enhancements, wide adoption of 3D CBCT systems in dental implant procedures, and the growing focus on the evaluation of post-treatment cases are factors attributed to the large share of dental application.
By type, ENT segment accounted for the largest share of the non-dental application market in 2017
Based on the type, the non-dental application market is further segmented into ENT and radiology. In 2017, ENT segment accounted for the largest share of this market. This dominant share is attributed to the increasing use of CBT imaging in the diagnosis of ENT disorders due to advantages such as high spatial resolution, better visibility of small details, lower radiation exposure compared to traditional CT, patient convenience during examination, and compatibility of CBCT systems with surgical navigation/image-guided surgery systems during ear surgeries.
Europe accounted for the largest share of the EMEA 3D CBCT Systems Market in 2017, followed by the Middle East and Africa. The largest share of the European region is mainly attributed to the rising geriatric population, increasing awareness about oral healthcare, rising incidence of dental diseases, growing demand for advanced cosmetic dental procedures, growing dental tourism in some European countries, and the increasing number of dental clinics and hospitals in the region.
The key players in the EMEA 3D CBCT Systems Market are Danaher Corporation (US), DENTSPLY SIRONA (US), Carestream Dental (US), Planmeca Group (Finland), VATECH (South Korea), CEFLA (Italy), J. MORITA CORPORATION (Japan), ACTEON GROUP (France), Asahi Roentgen (Japan), and Genoray (South Korea).
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: